Contents 3 min read

Claim and source comparison

Compared the Lecaillon 1990 and Pavlík 1987 abstracts; methods, results and limitations sections of Lim 2026 and Liu 2025; the Wang 2026 abstract and the FDA letter. This limited reading is not an independent medical or complete clinical review.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human pharmacokinetic study

Lecaillon et al. (1990) found plasma half-lives of 10.6–68.1 hours after a single oral 800 mg dose of oxiracetam in 20 patients with varying renal function; elimination was slower with greater renal impairment.

This wide patient range is not a fixed half-life or dose-adjustment formula for healthy people. A general 8-hour value cannot calculate personal accumulation, medication timing or treatment of kidney disease.

Source 4 · Abstract read

Human randomized controlled trial

Lim et al. (2026) reported a 36-week placebo-controlled trial in 500 high-risk post-stroke participants; 457 completed it. Oxiracetam was not superior in changes in MMSE or CDR-SB (p=0.49 and p=0.38).

The primary outcomes did not support benefit in this selected stroke population. Physical activity was not randomized; exploratory subgroup or imaging signals cannot be converted into proven synergy or clinical prevention.

Source 5 · Full text read

Human randomized controlled trial

Liu et al. (2025) compared 14 days of intravenous L-oxiracetam, oxiracetam and placebo in 590 patients with traumatic brain injury. Day-90 LOTCA changes were 20.45, 15.90 and 11.47 respectively; the adjusted L-oxiracetam versus placebo difference was 8.97 points (95% CI 5.69–12.26).

This inpatient trial studied distinct enantiomer and intravenous products, not oral use in healthy people. Before the day-90 assessment, 146 participants withdrew; the LOTCA result does not establish benefit on every secondary measure or long-term safety.

Source 6 · Full text read

Animal study

Pavlík et al. (1987) reported increased hippocampal high-affinity choline uptake (HACU) after 6 days of pramiracetam or oxiracetam in male rats; striatal dopamine and HVA were unchanged.

This is an animal biochemical finding; it does not demonstrate human memory enhancement, choline deficiency or a need for choline supplementation. HACU measurement is not evidence of clinical efficacy or safe drug combinations.

Source 7 · Abstract read

Regulatory scientific assessment

The FDA’s 2019 Peak Nootropics warning letter addresses marketed treatment claims for aniracetam, oxiracetam and pramiracetam products; it does not recognize those products as approved safe and effective treatments.

This is a dated US regulatory record about the named seller and claims; it is not a current global approval map or a clinical experiment measuring a particular adverse-event rate. Online sale does not establish safety or approval.

Source 8 · Official summary read

Systematic review / meta-analysis

Wang et al. (2026) synthesized 33 randomized trials (2864 participants) in acute traumatic brain injury. In 10 trials with balanced background therapy (798 participants), the post-treatment MMSE difference was 4.67 points (95% CI 3.07–6.28; I²=92%).

This is a difference between post-treatment group means, not an individual’s change from baseline. Evidence certainty is low or very low; heterogeneity, risk of bias and incomplete harm reporting preclude conclusions about durable benefit, routine use or safe doses.

Source 9 · Abstract read

Our evidence and source methodology

Oxiracetam: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Oxiracetam?

Oxiracetam is a synthetic racetam. Post-stroke prevention and acute traumatic-brain-injury studies concern different patients, products and routes; they do not establish cognitive benefits or personal-use protocols for healthy people.

Mechanism of Effect

Pavlík et al. (1987) reported increased hippocampal high-affinity choline uptake (HACU) after 6 days of pramiracetam or oxiracetam in male rats; striatal dopamine and HVA were unchanged.

This is an animal biochemical finding; it does not demonstrate human memory enhancement, choline deficiency or a need for choline supplementation. HACU measurement is not evidence of clinical efficacy or safe drug combinations.

Clinical Evidence

Lim et al. (2026) reported a 36-week placebo-controlled trial in 500 high-risk post-stroke participants; 457 completed it. Oxiracetam was not superior in changes in MMSE or CDR-SB (p=0.49 and p=0.38).

The primary outcomes did not support benefit in this selected stroke population. Physical activity was not randomized; exploratory subgroup or imaging signals cannot be converted into proven synergy or clinical prevention.

Liu et al. (2025) compared 14 days of intravenous L-oxiracetam, oxiracetam and placebo in 590 patients with traumatic brain injury. Day-90 LOTCA changes were 20.45, 15.90 and 11.47 respectively; the adjusted L-oxiracetam versus placebo difference was 8.97 points (95% CI 5.69–12.26).

This inpatient trial studied distinct enantiomer and intravenous products, not oral use in healthy people. Before the day-90 assessment, 146 participants withdrew; the LOTCA result does not establish benefit on every secondary measure or long-term safety.

Wang et al. (2026) synthesized 33 randomized trials (2864 participants) in acute traumatic brain injury. In 10 trials with balanced background therapy (798 participants), the post-treatment MMSE difference was 4.67 points (95% CI 3.07–6.28; I²=92%).

This is a difference between post-treatment group means, not an individual’s change from baseline. Evidence certainty is low or very low; heterogeneity, risk of bias and incomplete harm reporting preclude conclusions about durable benefit, routine use or safe doses.

Dose information and research limits

Lecaillon et al. (1990) found plasma half-lives of 10.6–68.1 hours after a single oral 800 mg dose of oxiracetam in 20 patients with varying renal function; elimination was slower with greater renal impairment.

This wide patient range is not a fixed half-life or dose-adjustment formula for healthy people. A general 8-hour value cannot calculate personal accumulation, medication timing or treatment of kidney disease.

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Safety and Side Effects

Oxiracetam elimination varies with renal function. Limited or incomplete adverse-event reporting in trauma studies does not establish long-term or drug-combination safety; do not change prescribed treatment on your own.

The FDA’s 2019 Peak Nootropics warning letter addresses marketed treatment claims for aniracetam, oxiracetam and pramiracetam products; it does not recognize those products as approved safe and effective treatments.

This is a dated US regulatory record about the named seller and claims; it is not a current global approval map or a clinical experiment measuring a particular adverse-event rate. Online sale does not establish safety or approval.

Sources

  1. Gouliaev, A.H., Senning, A. (1994). Piracetam and other structurally related nootropics. Brain Research Reviews, 19(2), 180–222. PubMed · PMID 8061686
  2. Itil TM, Menon GN, Bozak M, Songar A. (1982). The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam). Drug Development Research, 2(5), 447–461. https://doi.org/10.1002/ddr.430020506 Publisher record · DOI · Wiley
  3. Malykh, A.G., Sadaie, M.R. (2010). Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs, 70(3), 287–312. PubMed · PMID 20166767
  4. Lecaillon JB, et al. (1990). Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose. European Journal of Drug Metabolism and Pharmacokinetics, 15(3), 231–7. https://doi.org/10.1007/BF03190209 PubMed · PMID 2253654
  5. Lim JS, et al. (2026). Oxiracetam and physical activity in preventing cognitive decline after stroke: A multicenter, randomized controlled trial. European Stroke Journal, 11(1), 23969873251350141. https://doi.org/10.1093/esj/23969873251350141 PubMed · PMID 41614470
  6. Liu T, et al. (2025). Efficacy and safety of L-oxiracetam on cognitive function in patients with traumatic brain injury: a multicentre, randomised, double-blind, phase 3 clinical trial. Signal Transduction and Targeted Therapy, 10, 401. https://doi.org/10.1038/s41392-025-02492-5 PubMed · PMID 41381424
  7. Pavlík A, Benesová O, Dlohozková N. (1987). Effects of nootropic drugs on brain cholinergic and dopaminergic transmission. Activitas Nervosa Superior, 29(1), 62–65. PubMed · PMID 3035858
  8. US Food and Drug Administration. (2019). Warning Letter: Peak Nootropics LLC aka Advanced Nootropics. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-nootropics-llc-aka-advanced-nootropics-557887-02052019 US Food and Drug Administration
  9. Wang M, Cao N, Shou Z, Pan J. (2026). Efficacy and safety of oxiracetam for cognitive and functional outcomes after acute traumatic brain injury in Chinese populations: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology, 17, 1894256. https://doi.org/10.3389/fphar.2026.1894256 PubMed · PMID 42835276

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions